Difference between revisions of "Team:DTU-Denmark/products"

Line 3: Line 3:
 
<html lang="en">
 
<html lang="en">
 
<head>
 
<head>
 +
    <!-- Edited by Isabella 7-9-16 14:30 in sidebar - remove xs-hidden from sidebar -->
 +
    <!-- Edited by Isabella 26-9-16-14:22 fix white space above picture, do not edit the spaces between things this create unintentional space-->
 
     <title>Bootstrap Example</title>
 
     <title>Bootstrap Example</title>
 
     <meta charset="utf-8">
 
     <meta charset="utf-8">
Line 20: Line 22:
 
                 <div class="caption">
 
                 <div class="caption">
 
                     <div class="col-md-5 col-sm-5 col-xs-12 title"> <!-- the approximate max number of characters ~ 400 --> <!-- EDIT -->
 
                     <div class="col-md-5 col-sm-5 col-xs-12 title"> <!-- the approximate max number of characters ~ 400 --> <!-- EDIT -->
                         <h1>Molecular toolbox<p class="lead">In the substrate section we established that <i>Yarrowia Lipolytica</i> constitutes a great platform utilizing waste streams. In order to unlock the potential of <i>Y. Lipolytica</i>, we developed a molecular toolbox allowing us to efficiently engineering <i>Y. Lipolytica</i>. In this section we present the theory and results of the development of a BioBrick backbone and CRISPR tools for <i>Y. Lipolytica</i></p></h1>
+
                         <h1>Products<p class="lead">In the Molecular tools section we developed several molecular tools, potentially allowing us to genetically engineer <i><i>Y. lipolytica</i></i>. In this section we apply these tools and attempt to use these to achieve expression in <i>Y. lipoltyca</i>.</p></h1>
 
                     </div>
 
                     </div>
 
                     <div class="col-md-2 col-sm-2 hidden-xs space"></div>
 
                     <div class="col-md-2 col-sm-2 hidden-xs space"></div>
 
                     <div class="col-md-5 col-sm-5 hidden-xs intro"> <!-- will be hidden on phones, duplicate the text to blockquote down below first section header, to show it there, when it dissapear-->
 
                     <div class="col-md-5 col-sm-5 hidden-xs intro"> <!-- will be hidden on phones, duplicate the text to blockquote down below first section header, to show it there, when it dissapear-->
 
                         <blockquote class="blockquote-reverse"> <!-- EDIT -->
 
                         <blockquote class="blockquote-reverse"> <!-- EDIT -->
                             <p>Man is a tool-using animal. Without tools he is nothing, with tools he is all.</p>
+
                             <p>“Productivity is never an accident. It is always the result of a commitment to excellence, intelligent planning, and focus efforts”
                             <small>Thomas Carlyle <cite title="Source Title">Signs of the Times (1829)</cite></small>
+
                             <small>Paul J. Meyer <cite title="Source Title">It's your life. Live big.</cite></small>
 
                         </blockquote>       
 
                         </blockquote>       
 
                     </div>
 
                     </div>
Line 32: Line 34:
 
             </div>
 
             </div>
 
         </div> <!-- /row -->
 
         </div> <!-- /row -->
 +
        <div class="border"></div>
 
     </div>
 
     </div>
 
</div> <!-- /masthead-->
 
</div> <!-- /masthead-->
Line 38: Line 41:
 
<!-- Content -->
 
<!-- Content -->
 
<div class="container">
 
<div class="container">
<div class="row"> <!--Must sorround both content and sidebar-->  
+
<div class="row"> <!--Must sorround both content and sidebar-->
     <div class="col-md-9 col-sm-10 colLeft"> <!-- LEFT -->      
+
     <div class="col-md-9 col-sm-10 colLeft"> <!-- LEFT -->
 
         <div><a class="anchor" id="section-1"></a>
 
         <div><a class="anchor" id="section-1"></a>
            <h2 class="h2">BioBrick plasmid</h2>
+
        <h2 class="h2">Introduction</h2>
             <h3 class="h3">Introduction</h3>
+
           
 +
             <blockquote class="visible-xs"> <!-- quote from masterhead duplicate -->
 +
                <p>“Productivity is never an accident. It is always the result of a commitment to excellence, intelligent planning, and focus efforts”<sup><a href="#references"> 3</a></sup></p>
 +
                <small>Paul J. Meyer <cite title="Source Title">It's your life. Live big.</cite><</small>
 +
            </blockquote>
 +
           
 
             <p>
 
             <p>
                 A key part of synthetic biology is to streamline the process of engineering biological systems, by standardizing parts and methods<sup><a href="#references">1</a></sup>. Perhaps the most versatile standards available is the BioBrick standard, in part due to the contributions made during the annual iGEM competition. The BioBrick registry currently has over 20,000<sup><a href="#references">2</a></sup>, and by creating BioBrick plasmid backbones compatible with a new organism, one is effectively unlocking the entire BioBrick registry available for that specific organism. Realizing this, it was decided to develop a plasmid that supports the BioBrick standard and replicates in <i>Y. Lipolytica</i>. Due to the convenience of manipulating <i>Escherichia coli</i> it was determined to develop a shuttle vector that allows for cloning and confirmation of the construct in <i>E. coli</i>, before the construct is transformed in <i>Y. Lipolytica</i>. Additionally, as the only replicative plasmids currently available for <i>Y. Lipolytica</i> is low copy yeast chromosomal plasmids (YCp)<sup><a href="#references">3</a></sup> this allows for high amounts of DNA to easily be propagated in <i>E. coli</i>, before the the plasmid is purified and transformed into <i>Y. Lipolytica</i>. Figure 1 shows a suggested workflow for the proposed BioBrick plasmid.
+
                 By developing tools to genetically engineer <i>Yarrowia lipolytica</i> we aim to create a versatile cell factory, which in the future will be able to produce almost any desired product ranging from complex therapeutic proteins to high value chemical compounds. Besides diversity of products cell factory based on <i>Yarrowia lipolytica</i> offers a wide range of substrate tolerance.  
 
             </p>
 
             </p>
 
            <!-- image with figure caption and modal that load the same picture -->
 
            <figure class="figure">
 
                <img id="img1" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/8/8f/T-DTU-Denmark-Cloning_diagram1.png" alt="DESCRIPTION">
 
                <figcaption class="figure-caption"><strong>Figure 1:</strong> The suggested workflow using pSB1A8YL described above. The workflow is broken down to three distinct steps: cloning, confirmation and expression. Cloning is the assembly of the construct, which is conducted in <i>E. coli</i> using typical cloning methods. Confirmation is where the identity of the construct is confirmed, using analytical methods such as PCR, analytical restriction enzyme digestion and/or sequencing. Expression includes the work done in the final host organism, <i>Y. lipolytica</i>, and includes inserting the construct and optimization of the expression and cultivation conditions.</figcaption>
 
            </figure>
 
 
            <!-- The Modal with same picture-->
 
            <div id="img1Modal" class="modal">
 
                <span class="close img1">×</span>
 
                <img class="modal-content" id="img1Img">
 
                <div class="caption">DESCRIPTION</div>
 
            </div>
 
 
        <h3 class="h3">Design</h3>
 
 
             <p>
 
             <p>
            For the design of the plasmid, we decided to incorporate a high copy <i>E. coli</i> part for cloning and propagation DNA. The design was based on the pUC19 vector as it fulfils the criteria of being high copy<sup><a href="#references">4</a></sup>, while perhaps being one of the most widely used cloning vectors for <i>E. coli</i>. To support the BioBrick standard, we only used the ampicillin resistance and replication origin elements of the plasmid. It was found that the sequence in and between these elements did not contain any restriction sites of any current BioBrick assembly standard, thus no further modification of the sequence was needed.
+
                We aim to demonstrate this versatility of our <i>Y. lipolytica</i> strain as a cell factory by producing heterologous proteins. Our first attempt is the production of hrGFP, followed by proinsulin. To achieve both of mentioned ideas we apply the pSB1A8YL plasmid, cloning workflow and codon optimization algorithm developed by our team.  
 
             </p>
 
             </p>
           
+
        </div> <!-- /overview-->
            <div class="row">
+
       
                <div class="col-md-6">
+
                    <p>
+
                    For the <i>Y. Lipolytica</i> part of the plasmid we decided to base the design on the pSL16-CEN1-1(227), as it has found to exhibit high transformation efficiency compared to similar plasmids<sup><a href="#references">5</a></sup>, and perhaps for this reason this plasmid and its derivatives are utilized in many recent studies.<sup><a href="#references">6,7,8</a></sup> Again only the sequence of the replicative and selective elements were chosen. Although, the original sequence was not BioBrick compatible, and thus it was decided to order the sequence as a gBlock. This also introduced the added benefit of being able to incorporate the BioBrick prefix, suffix and a 5’ terminator in the gBlock and exchange the original leucine autotrophy marker with a uracil autotrophy marker allowing for negative selection of the plasmid with 5-Fluoroorotic Acid (5-FOA)<sup><a href="#references">9</a></sup>. In order to comply with the iGEM plasmid nomenclature<sup><a href="#references">10</a></sup>, the plasmid was dubbed “pSB1A8YL”, YL was added in the end to emphasize that the plasmid is used for <i>Y. Lipolytica</i>. Figure 2 shows a graphical representation of the sequence map of pSB1A8YL.
+
                    </p>
+
                </div>
+
               
+
                <div class="col-md-6">
+
                    <figure class="figure">
+
                        <img id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/f/f0/T--DTU-Denmark--pSB1A8YL_Sequence_map.png/603px-T--DTU-Denmark--pSB1A8YL_Sequence_map.png" alt="DESCRIPTION">
+
                        <figcaption class="figure-caption"><strong>Figure 2:</strong> Sequence map of pSB1A8YL. The colored blocks represents the following: Orange: pUC19 part, Blue modified pSL16-CEN1-1(227) part, pink: BioBrick prefix, purple: BioBrick suffix, red: terminator, green selection markers, grey: origin of replication.  The full annotated sequence can be found <a href="http://parts.igem.org/Part:BBa_K2117009">HERE</a>. </figcaption>
+
                    </figure>
+
                   
+
                    <!-- The Modal with same picture-->
+
                    <div id="img2Modal" class="modal">
+
                        <span class="close img2">×</span>
+
                        <img class="modal-content" id="img2Img">
+
                        <div class="caption">DESCRIPTION</div>
+
                    </div>
+
                </div>
+
            </div>
+
  
         <h3 class="h3">Cloning</h3>
+
       
            <div class="row">
+
         <div><a class="anchor" id="section-2"></a>
               
+
        <h2 class="h2">hrGFP</h2>
                <div class="col-md-6">
+
            <h3 class="h3">Design</h3>
                    <figure class="figure">
+
                <p>
                        <img id="img3" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/0/0b/T--DTU-Denmark--pSB1A8YL_PCR_fragments.png/589px-T--DTU-Denmark--pSB1A8YL_PCR_fragments.png" alt="DESCRIPTION" width="350">
+
            In order to test if we were able to clone a of a construct in <i>E. coli</i> pSB1A8YL, which would be expressed, and ultimately prove that we were able to express genes in <i>Y. lipolytica</i>, we chose to develop our own BioBricks. Namely a constitutive transcription factor alpha (TEF1) promoter native to <i>Y. lipolytica</i> (<a href="http://parts.igem.org/Part:BBa_K2117000">BBa_K2117000</a>) and the hrGFP gene (<a href="http://parts.igem.org/Part:BBa_K2117003">BBa_K2117003</a>) previously used successfully in <i>Y. lipolytica</i><sup><a href="#references">1</a></sup>. The hrGFP sequence was codon optimized by the algorithm developed by our team. By combining these two parts in a device (<a href="http://parts.igem.org/Part:BBa_K2117005">BBa_K2117005</a>) the expression should, in theory, be easily detected due to the fluorescence signal produced. The cloning flow can be seen in Figure 1.
                        <figcaption class="figure-caption"><strong>Figure 3:</strong> PCR fragments with USER tails, which were fused to construct pSB1A8YL. The fragment lengths can be seen on the ladder. The primers used and the theretical fragment length can be seen under the bands.</figcaption>
+
                    </figure>
+
                   
+
                    <!-- The Modal with same picture-->
+
                    <div id="img3Modal" class="modal">
+
                    <span class="close img3">×</span>
+
                    <img class="modal-content" id="img3Img">
+
                    <div class="caption">DESCRIPTION</div>
+
                    </div>
+
                </div>
+
                <div class="col-md-6">
+
                    <p>
+
                    The pUC19 part and the gBlock fragments was amplified using primers with USER tails, and fused using USER cloning (See Figure 3).
+
                    </p>
+
                </div>
+
            </div>
+
           
+
            <p>
+
            The USER reactions was transformed into chemically competent <i>E. coli</i> DH5alpha cells, and purified. The identity of the product was checked using PCR, restriction analysis (see Figure 4) and sequencing (data not shown).
+
 
             </p>
 
             </p>
 +
 
             <figure class="figure">
 
             <figure class="figure">
                <img id="img4" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/7/7d/T--DTU-Denmark--pSB1A8YL_confirmation.png" alt="DESCRIPTION">
+
            <img id="img1" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/f/f8/T--DTU-Denmark--Cloning_flow2.png/800px-T--DTU-Denmark--Cloning_flow2.png" alt="DESCRIPTION">
                <figcaption class="figure-caption"><strong>Figure 4:</strong> pSB1A8YL undigested and linearized. Analytical PCRs are also included in the right of the gel picture. The fragment lengths can be seen on the ladder. The restriction enzymes and primers used and the theretical fragment length can be seen under the bands</figcaption>
+
            <figcaption class="figure-caption"><strong>Figure 1:</strong> Cloning flow of the expression test of pSB1A8YL in <i>Y. lipolytica</i>. The expression of the GFP should yield a flourescent ouput detectable by fluorescence microscopy or fluorometer measurements.</figcaption>
 
             </figure>
 
             </figure>
  
 
             <!-- The Modal with same picture-->
 
             <!-- The Modal with same picture-->
             <div id="img4Modal" class="modal">
+
             <div id="img1Modal" class="modal">
                <span class="close img4">×</span>
+
            <span class="close img1">×</span>
                <img class="modal-content" id="img4Img">
+
            <img class="modal-content" id="img1Img">
                <div class="caption">DESCRIPTION</div>
+
            <div class="caption">DESCRIPTION</div>
 
             </div>
 
             </div>
  
         
+
            <h3 class="h3">Results</h3>
        <h3 class="h3">Testing</h3>
+
 
             <p>
 
             <p>
             After having confirmed the identity of the plasmid, we set out to test its functionality. This was done by: 1. Testing the plasmids replicability and selectivity in <i>Y. Lipolytica</i> and 2. testing the plasmids cloning capabilities in <i>E. coli</i>.  
+
             The parts were ordered as gBlocks and assembled in <i>E. coli</i> using A3 assembly. The assembly was confirmed using restriction analysis (See Figure 2), PCR and sequencing (data not shown).
 
             </p>
 
             </p>
  
            <h5 class="h5">1. Replicability and selectability in Yarrowia lipolytica</h5>
 
           
 
            <div class="row">
 
             
 
              <div class="col-md-6">
 
                  <p>
 
                    The pSB1A8YL plasmid was purified from <i>E. coli</i> DH5alpha, and transformed in <i>Y. Lipolytica</i> PO1f cells. The transformants was selected on selective dropout media not containing uracil, thus only yielding uracil autotroph transformants. A negative control was included substituting the plasmid for MQ water.
 
                    The transformations only yielded colonies on the plated containing the cells which were transformed with the plasmid. To ensure that these results indeed meant that our plasmid was stably replicating in the <i>Y. Lipolytica</i> cells, a few colonies were subjected to colony PCR (see Figure 5).
 
                    </p>
 
                    <p>
 
                    These results confirm that pSB1A8YL replicates in <i>Y. Lipolytica</i>, and the chosen uracil selection marker allows for selection of transformants.
 
                    To further assess the functionality of pSB1A8YL, the possibility of counter selection was investigated. This was done by growing colonies containing pSB1A8YL on plates containing 5-FOA. Colonies appearing on these plates were then transferred to selective dropout media not containing uracil. As no growth was observed on the latter plate, this proved that pSB1A8YL supports counter selection.
 
                    </p>
 
              </div>
 
             
 
                <div class="col-md-6">
 
                    <figure class="figure">
 
                    <img id="img5" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/3/34/T--DTU-Denmark--pSB1A8YL_Ylip_cPCR.png/519px-T--DTU-Denmark--pSB1A8YL_Ylip_cPCR.png" alt="DESCRIPTION" width="350">
 
                    <figcaption class="figure-caption"><strong>Figure 5:</strong> Colony PCR of pSB1A8YL in <i>Y. lipolytica</i>. The fragment lengths can be seen on the ladder. The primers used and the theoretical fragment length can be seen under the bands</figcaption>
 
                    </figure>
 
                   
 
                    <!-- The Modal with same picture-->
 
                    <div id="img5Modal" class="modal">
 
                    <span class="close img5">×</span>
 
                    <img class="modal-content" id="img5Img">
 
                    <div class="caption">DESCRIPTION</div>
 
                    </div>
 
                </div>
 
            </div>
 
           
 
           
 
           
 
<h5 class="h5">2. Cloning capabilities in <i>E. coli</i></h5>
 
            <p>
 
            In order to test this, we decided to produce a device using BioBricks from the distribution kit which would allow us to easily assess whether the cloning were successful. When deciding BioBricks that would allow this, we received inputs from the SDU iGEM team. We ended up choosing the strong Andersson promoter/strong RBS BioBrick (<a href="http://parts.igem.org/Part:BBa_K880005">BBa_K880005</a>) and pair this with three chromoproteins: amilCP (<a href="http://parts.igem.org/Part:BBa_K592009">BBa_K592009</a>), amilGFP (<a href="http://parts.igem.org/Part:BBa_K592010">BBa_K592010</a>) and mRFP (<a href="http://parts.igem.org/Part:E1010">BBa_E1010</a>), which would allow us to easily pick transformants and visually inspect if the cloning was successful. The cloning flow is shown in Figure 6.
 
            </p>
 
 
             <figure class="figure">
 
             <figure class="figure">
             <img id="img6" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/c/c7/T--DTU-Denmark--Cloning_flow1.png/800px-T--DTU-Denmark--Cloning_flow1.png" alt="DESCRIPTION">
+
             <img id="img4" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/9/99/T--DTU-Denmark--TEF%2BGFP_restriction_analysis.jpg/246px-T--DTU-Denmark--TEF%2BGFP_restriction_analysis.jpg" alt="DESCRIPTION" width="150">
             <figcaption class="figure-caption"><strong>Figure 6:</strong> Cloning flow of the test of pSB1A8YL in <i>E. coli</i>. The expression of the chromoproteins should yield a color ouput detectable by visual inspection.</figcaption>
+
             <figcaption class="figure-caption"><strong>Figure 2:</strong> Analytical digestion of the pSB1A8YL containing the <a href="http://parts.igem.org/Part:BBa_K2117005">BBa_K2117005</a> device. The fragment lengths can be seen on the ladder, and the restriction enzyme and predicted fragment lengths is stated above the fragments.</figcaption>
 
             </figure>
 
             </figure>
  
 
             <!-- The Modal with same picture-->
 
             <!-- The Modal with same picture-->
             <div id="img6Modal" class="modal">
+
             <div id="img4Modal" class="modal">
             <span class="close img6">×</span>
+
             <span class="close img4">×</span>
             <img class="modal-content" id="img6Img">
+
             <img class="modal-content" id="img4Img">
 
             <div class="caption">DESCRIPTION</div>
 
             <div class="caption">DESCRIPTION</div>
 
             </div>
 
             </div>
 +
 
             <p>
 
             <p>
             The BioBricks were retrieved from the distribution kit, and assembled with our plasmid as carrier backbone using standard 3A assembly and transformed into chemically competent <i>E. coli</i> DH5alpha cells. The transformants yielded colored colonies (See Figure 7), and the identity of the constructs were confirmed using restriction analysis and PCR (data not shown). These results confirm that pSB1A8YL can be used for cloning in <i>E. coli</i> and supports the BioBrick standard.
+
             Afterwards the construct was transformed into <i>Y. lipolytica</i> PO1f and grown on plates containing selective media. Single colonies were picked and grown in liquid selective media, and subjected to fluorescence microscopy. Figure 3 shows the <i>Y. lipolytica</i> PO1f cells under a confocal laser microscope with 100x magnification. The high fluorescent output from with the <a href="http://parts.igem.org/Part:BBa_K2117005">BBa_K2117005</a> construct, proves that the cells are producing hrGFP, and ultimately that our expression system consisting of pSB1A8YL and the TEF1 promoter (<a href="http://parts.igem.org/Part:BBa_K2117000">BBa_K2117000</a>) can be used for heterologous protein expression in <i>Y. lipolytica</i>.
 
             </p>
 
             </p>
  
 
             <figure class="figure">
 
             <figure class="figure">
             <img id="img7" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/8/85/T--DTU-Denmark--Colored_colonies.png/799px-T--DTU-Denmark--Colored_colonies.png" alt="DESCRIPTION">
+
             <img id="img2" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/6/60/T--DTU-Denmark--GFP_Tef%2BhrGFP_all.png" alt="DESCRIPTION">
 
             </figure>
 
             </figure>
  
 
             <!-- The Modal with same picture-->
 
             <!-- The Modal with same picture-->
             <div id="img7Modal" class="modal">
+
             <div id="img2Modal" class="modal">
             <span class="close img7">×</span>
+
             <span class="close img2">×</span>
             <img class="modal-content" id="img7Img">
+
             <img class="modal-content" id="img2Img">
 
             <div class="caption">DESCRIPTION</div>
 
             <div class="caption">DESCRIPTION</div>
 
             </div>
 
             </div>
  
 
             <figure class="figure">
 
             <figure class="figure">
             <img id="img8" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/3/3c/T--DTU-Denmark--Color_constructs_restriction_analysis.png/799px-T--DTU-Denmark--Color_constructs_restriction_analysis.png" alt="DESCRIPTION">
+
             <img id="img3" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/4/40/T--DTU-Denmark--GFP_control.png" alt="DESCRIPTION" width="478">
             <figcaption class="figure-caption"><strong>Figure 7:</strong> Actual results from the test of pSB1A8YL in <i>E. coli</i>. Top: A color output was visible both in liquid culutres, pellets and on plates. Bottom: Restriction analysis of the constructs. The fragment lengths can be seen on the ladder. The restriction enzymes used and the theretical fragment length can be seen under the bands</figcaption>
+
             <figcaption class="figure-caption"><strong>Figure 3:</strong> Fluorescence microscopy conducted by a confocal laser microscope with 100x magnification. A and D are taken using standard brightfield, B and E are taken using the GFP filter and with the excitation laser on and C and F are overlays of the two photos where the black bagground has been removed (C is an overlay of A and B, and F is an overlay of D and E). A, B and C are <i>Y. lipolytica</i> PO1f cells with our GFP expressing device (<a href="http://parts.igem.org/Part:BBa_K2117005">BBa_K2117005</a>) shuttled by our plasmid pSB1A8YL. D, E and F are <i>Y. lipolytica</i> PO1f cells with the empty pSB1A8YL plasmid, which serves as a control for the GFP signal. Notice that even though the empty vector control shows trace amounts of auto-fluoresence the strain with the GFP expressing device clearly exhibits higher levels of fluorescence, which proves that our expression system works as intended.</figcaption>
 
             </figure>
 
             </figure>
  
 
             <!-- The Modal with same picture-->
 
             <!-- The Modal with same picture-->
             <div id="img8Modal" class="modal">
+
             <div id="img3Modal" class="modal">
             <span class="close img8">×</span>
+
             <span class="close img3">×</span>
             <img class="modal-content" id="img8Img">
+
             <img class="modal-content" id="img3Img">
 
             <div class="caption">DESCRIPTION</div>
 
             <div class="caption">DESCRIPTION</div>
 
             </div>
 
             </div>
Line 207: Line 126:
 
         </div>
 
         </div>
 
          
 
          
         <div><a class="anchor" id="section-2"></a>
+
         <div><a class="anchor" id="section-3"></a>
         <h2 class="h2">CRISPR</h2>
+
         <h2 class="h2">Insulin</h2>
             <h3 class="h3">Introduction</h3>
+
            Our experiments told us that our plasmid was a powerful tool, allowing us to conveniently assembling constructs in <i>E. coli</i>, which would be expressed in <i>Y. lipolytica</i>. Now we wanted to use it to take on the ultimate challange: Could we use this tool to produce proinsulin, and potentially increase the sustainability of insulin production?
 +
             <h3 class="h3">Theory</h3>
 
                 <p>
 
                 <p>
                     By creating a modular plasmid that is compatible with the BioBrick standards and that is able to replicate in both <i>E. coli</i> and <i>Y. lipolytica</i>, the entire biobrick registry has been made available for use in <i>Y. lipolytica</i>. However, one important aspect of industrial-scale protein expression is the stable and homogenous expression of relevant pathway genes. In production organisms with multi-enzyme pathways there is often a need for accurate control of the expression levels of the associated genes, both in terms of promoter strength and copy numbers<sup><a href="#references">11</a></sup>. Plasmid based systems for the expression of heterologous genes are widely used, but offer limited control of copy number and in many cases show notable segregational instability even during growth in selective media. Therefore, it is often preferred to integrate the genetic pathway of interest into the genome of the production organism of choice to ensure long-term strain stability and homogenous expression of pathway genes<sup><a href="#references">11</a></sup>.
+
                     Insulin is a peptrode hormone synthesised in the pacreas, and plays a crucial role in glucose homeostasis and prevents harmful levels of sugar in the blood. Beta-cells in the islets of the pancreas release insulin to the blood stream, which stimulates muscle fat and liver cells to absorb and store glucose from the bloodstream by interacting with insulin-specific receptors<sup><a href="#references">2</a></sup>. Diabetes is caused by either immune-mediated destruction of pacreatic islet cells (type 1 diabetes), or pancreatic exhaustion causing insulin resistance (type 2 diabetes). Both types of diabetes is cured by artificially controlling the insulin concentration in the patient by injection<sup><a href="#references">3</a></sup>. The treatment of diabetes with insulin was discovered in 1921, and its ability to restore health is so dramatic, that it was initially described in terms such as "the raising of the dead". Considering this it perhaps does not come as a surprise that insulin is often descirbed as one of the most important biomedical events of the last century<sup><a href="#references">4</a></sup>, and as the number of adults with diabetes is expected to rise from 415 million today to 642 million in 2040, the relevance of diabetes is higher than ever<sup><a href="#references">6</a></sup>. To read more about the insulin market, see our descriptions page.
 
                 </p>
 
                 </p>
             
+
            <h3 class="h3">Insulin biosynthesis</h3>
 
                 <p>
 
                 <p>
                     The CRISPR-Cas9 has revolutionized the way in which model organisms can be engineered. In addition, it has made genetic engineering applicable to a wide range of organisms that were previously considered to be uninteresting for cell factory purposes, largely because the genetic engineering tools for these organisms were under characterized. The CRISPR-Cas9 system is ideally suited for the integration of heterologous genes in production organisms, as it relies on Double Strand Break (DSB) induction and its subsequent repair by homologous recombination (HR). In addition, almost any sequence of interest can be targeted with the most commonly used Cas9 from <i>Streptococcus pyogenes</i><sup><a href="#references">12</a></sup>. The basic mechanism of CRISPR-Cas9 is illustrated in Figure 9, for a more detailed overview the reader is referred to Nødvig et al.<sup><a href="#references">12</a></sup>
+
                     At the first stage insulin is synthesized as a chain of 101 amino acids, called preproinsulin with a molecular weight of 12 Kilo daltons (kDa), which comprises of signal peptide (pre-peptide) and three short chains: A, B and C. The pre-peptide, responsible for directing a nascent polypeptide, is removed from preproinsulin giving the proinsulin consisting of 86 amino acids with a molecular weight of 9.4kDa. Subsequently, the proinsulin is folded and two disulphide bonds are created between chain A and B and one links chain A. In the last step, the C chain is digested from the proinsulin by an exoprotease - carboxypeptidase E. The mature insulin contains chains A and B linked by 3 disulphide bonds and in total comprises of 51 amino acids with a molecular weight of 5.8kDa<sup><a href="#references">5</a></sup>.
 +
                </p><p>
 +
                    FIGURE OF INSULIN CHAINS AND CLEAVING
 
                 </p>
 
                 </p>
           
+
                    The first insulin was extracted from animals, and <i>E. coli</i> was emplyoed in the production of the A and B chain separately as recombinant DNA technologies progessed. Today insulin is produced in <i>Saccharomyces cerevisiae</i> by a single chain nonnative "miniproinsulin" precursor, which is matured by trypsin and carboxypeptidase B<sup><a href="#references">4</a></sup>.
                <figure class="figure">
+
            <h3 class="h3">Goal</h3>
                <img id="img10" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/8/8d/T--DTU-Denmark--CRISPRCas9overview.png" alt="DESCRIPTION">
+
                <figcaption class="figure-caption"><strong>Figure 9:</strong> Overview of the CRISPR-Cas9 mechanism of DSB induction. The systems consists of two components, the endonuclease Cas9 and a sgRNA. Cas9 is targeted for site-specific DSB induction by the sgRNA. More specifically, a 20 bp region of the sgRNA, known as the protospacer, recognizes the target site through base-pairing. This 20 bp protospacer is easily substituted, allowing for a very modular system. The only restriction for the CRISPR-Cas9 system is the requirement for a Protospacer Adjacent Motif (PAM) in the target region. For the most commonly used Cas9 (from <i>Streptococcus pyogenes</i>) this is the frequently occurring NGG sequence. Reproduced from Nødvig et al.<sup><a href="#references">12</a></sup></figcaption>
+
                </figure>
+
 
+
                <!-- The Modal with same picture-->
+
                <div id="img10Modal" class="modal">
+
                <span class="close img10">×</span>
+
                <img class="modal-content" id="img10Img">
+
                <div class="caption">DESCRIPTION</div>
+
                </div>
+
               
+
 
                 <p>
 
                 <p>
                     We adapt the CRISPR-Cas9 system for use also in <i>Y. lipolytica</i> in order to obtain a proof-of-concept of the construction of a stable production strain. We do so by a proof-of-concept integration of a gene in <i>Y. lipolytica</i>. In addition, we obtain a proof-of-concept of the deletion of a native <i>Y. lipolytica</i> gene. With these proof-of-concepts, we envision that the metabolic flux towards a possible compound of interest could be increased, leading to tailored <i>Y. lipolytica</i> strains for cell factory engineering purposes.
+
                     In order to demonstrate <i>Yarrowia lipolytica</i> as a versatile cell factory we aim to produce proinsulin as an answer to increasing global demand for insulin.
 
                 </p>
 
                 </p>
                       
+
             <h3 class="h3">Results</h3>
               
+
             <h3 class="h3">Experimental design</h3>
+
 
                 <p>
 
                 <p>
                     The CRISPR-Cas9 system has previously been successfully applied to <i>Y. lipolytica</i> by Schwartz et al.<sup><a href="#references">8</a></sup> As this was a proof-of-concept study, the native <i>Y. lipolytica</i> <i>PEX10</i> gene was targeted for disruption, which allowed for an easily selectable phenotype. This is because <i>PEX10</i> codes for Peroxisome biogenesis factor 10, a protein that is involved in peroxisome biogenesis. Consequently, <i>PEX10</i> disruption results in an inability to catabolize long-chain fatty acids. We set out to confirm the observed <i>PEX10</i> deletion. In addition, we set out to integrate <i>URA3</i>, a commonly used yeast auxotrophic marker gene which codes for Orotidine 5’-phosphate decarboxylase, an enzyme involved in pyrimidine biosynthesis.
+
                     The human proinsulin sequence was obtain from Sures et al. (1980). The sequence was codon optimized for the codon bias of <i>Y. lipolytica</i> using the codon optimization tool developed by our team, and ordered as a gBlock. The proinsulin gene with the RFC10 prefix and suffix was amplified by PCR into our BioBrick <a href="http://parts.igem.org/Part:BBa_K2117003">BBa_K2117003</a> and assembled with our TEF1 promoter to form our device <a href="http://parts.igem.org/Part:BBa_K2117002">BBa_K2117002</a>. This was done in pSB1A8YL using standard A3 assembly. The construct was transformed into <i>E. coli</i>, purified and confirmed using analytical digenstion, PCR and sequencing (data not shown). After confirmation of the construct, it was transformed into <i>Y. lipolytica</i>. The transformants was subjected to colony PCR (see Figure 4). The cloning flow can be seen in Figure 5.
 
                 </p>
 
                 </p>
           
 
                <p>
 
                    We had obtained both a commonly used <i>Y. lipolytica</i> laboratory strain (PO1f, <i>MATA</i> <i>URA3</i>-­302 <i>LEU2</i>-­270 <i>XPR2</i>-­322 <i>AXP2</i> ­Δ<i>NU49</i> <i>XPR2::SUC2</i>; obtained from Schwartz et al.<sup><a href="#references">8</a></sup>) and also this same strain with a knockout of the Non-Homologous End-Joining (NHEJ) DNA repair pathway gene <i>Ku70</i> (PO1fΔ<i>Ku70</i>, <i>MATA</i> <i>URA3</i>-­302 <i>LEU2</i>-­270 <i>XPR2</i>-­322 <i>AXP2</i> ­Δ<i>NU49</i> Δ<i>Ku70</i> <i>XPR2::SUC2</i>; obtained from Schwartz et al.<sup><a href="#references">8</a></sup>). The NHEJ pathway for DNA repair is commonly disrupted in laboratory strains to improve the efficiency of CRISPR-Cas9 induced HR integration of heterologous DNA. However, an intact NHEJ pathway can be utilized to disrupt genes without the need for an DNA repair template, as this pathway is intrinsically more error-prone than HR. Thus, in order to disrupt the native <i>Y. lipolytica</i> <i>PEX10</i> gene, we used a CRISPR-Cas9 plasmid (pCRISPRyl) in the PO1f strain. For the <i>URA3</i> insertion, we co-transformed the same CRISPR-Cas9 plasmid and a linearized HR donor plasmid (pIW501) in the PO1fΔ<i>Ku70</i> strain. An overview of our workflow is provided in Figure 10. Overviews of the pCRISPRyl and pIW501 are provided in Figures 11 and 12, respectively.
 
                </p>
 
               
 
                <figure class="figure">
 
                <img id="img11" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/c/c0/T--DTU-Denmark--HRNHEJoverview.png" alt="DESCRIPTION">
 
                <figcaption class="figure-caption"><strong>Figure 10:</strong> Overview of the experimental design for the proof-of-concept of gene disruption and gene integration using CRISPR-Cas9. Left: transformation of pCRISPRyl should result in gene disruption through error-prone repair by NHEJ (bases shown in yellow). Right: co-transformation of pCRISPRyl and a HR donor plasmid (pIW501) should result in integration of the desired donor gene (bases shown in orange). For plasmid map details, see Figures 11 and 12. Adapted from Nødvig et al.<sup><a href="#references">12</a></sup></figcaption>
 
                </figure>
 
 
                <!-- The Modal with same picture-->
 
                <div id="img11Modal" class="modal">
 
                <span class="close img11">×</span>
 
                <img class="modal-content" id="img11Img">
 
                <div class="caption">DESCRIPTION</div>
 
                </div>
 
               
 
                <div class="col-md-6">
 
 
                     <figure class="figure">
 
                     <figure class="figure">
                    <img id="img12" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/8/86/T--DTU-Denmark--pcrispryl.png" alt="DESCRIPTION">
+
                        <img id="img5" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/e/e0/T--DTU-Denmark--TEF%2BProins_restriction_analysis_png.png/800px-T--DTU-Denmark--TEF%2BProins_restriction_analysis_png.png" alt="DESCRIPTION">
                    <figcaption class="figure-caption"><strong>Figure 11:</strong> Simplified map of pCRISPRyl. Cas9 is under control of a strong constitutive TEF-derived hybrid promoter and the strong CYC1 terminator. Replication origins for use in <i>E. coli</i> (ori) and <i>Y. lipolytica</i> (Cen1-1) & ORI1001) are shown in yellow. Selection markers for use in <i>E. coli</i> (<i>AmpR</i>) and <i>Y. lipolytica</i> (<i>LEU2</i>) are shown in cyan. The synthetic tRNA promoter for sgRNA expression is shown in purple. A novel protospacer can be inserted by linearization of the plasmid with AvrII and subsequent Gibson assembly of a 60 bp fragment containing the desired protospacer into the plasmid<sup><a href="#references">8</a></sup>. Obtained from Addgene (#70007).</figcaption>
+
                        <figcaption class="figure-caption"><strong>Figure 4:</strong> Analytical digestion of the pSB1A8YL containing the <a href="http://parts.igem.org/Part:BBa_K2117002">BBa_K2117002</a> device. The fragment lengths can be seen on the ladder, and the primers predicted fragment lengths is stated above the fragments.</figcaption>
 
                     </figure>
 
                     </figure>
               
+
 
 
                     <!-- The Modal with same picture-->
 
                     <!-- The Modal with same picture-->
                     <div id="img12Modal" class="modal">
+
                     <div id="img5Modal" class="modal">
                    <span class="close img12">×</span>
+
                        <span class="close img5">×</span>
                    <img class="modal-content" id="img12Img">
+
                        <img class="modal-content" id="img5Img">
                    <div class="caption">DESCRIPTION</div>
+
                        <div class="caption">DESCRIPTION</div>
 
                     </div>
 
                     </div>
                </div>
+
 
                <div class="col-md-6">
+
                    <figure class="figure">
                    <figure class="figure">
+
                        <img id="img6" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/d/de/T--DTU-Denmark--Cloning_flow3.png/800px-T--DTU-Denmark--Cloning_flow3.png" alt="DESCRIPTION">
                    <img id="img13" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/6/68/T--DTU-Denmark--piw501.png" alt="DESCRIPTION">
+
                        <figcaption class="figure-caption"><strong>Figure 5:</strong> The cloning flow of the proinsulin producing strain.</figcaption>
                    <figcaption class="figure-caption"><strong>Figure 12:</strong> Simplified map of pIW501. The HR donor fragment consists of two flanking regions of 1 kb (shown in grey) and the <i>URA3</i> promoter+CDS+terminator (only the CDS is depicted in purple). The flanking regions target the <i>PEX10</i> locus. The replication origin for use in <i>E. coli</i> (ori) is shown in yellow, the selection marker for use in <i>E. coli</i> (<i>AmpR</i>) is depicted in cyan. Prior to transformation in <i>Y. lipolytica</i>, the plasmid is linearized with BamHI in order to increase HR efficiency. Obtained from Schwartz et al.<sup><a href="#references">8</a></sup></figcaption>
+
 
                     </figure>
 
                     </figure>
               
+
 
 
                     <!-- The Modal with same picture-->
 
                     <!-- The Modal with same picture-->
                     <div id="img13Modal" class="modal">
+
                     <div id="img6Modal" class="modal">
                    <span class="close img13">×</span>
+
                        <span class="close img6">×</span>
                    <img class="modal-content" id="img13Img">
+
                        <img class="modal-content" id="img6Img">
                    <div class="caption">DESCRIPTION</div>
+
                        <div class="caption">DESCRIPTION</div>
 
                     </div>
 
                     </div>
                 </div>
+
                 <p>
                     
+
                    We knew that detecting the proinsulin would be the biggest challange yet, as all previous detections was based on chromoproteins and fluorescence, while this was a protein without any intrinsic detectable signal. We had several considerations for detecting the proinsulin production including rtPCR and ELISA, altough ended up chosing SDS page and Western blotting, as these methods provide excellent sensitivity while some of the experiences running the SDS page experiments could be transfered to the western blotting experiments. The results of these experiments are show in Figure 6 and 7.
            <h3 class="h3">Results & Discussion</h3>
+
                </p>
              <h5 class="h5">1. <i>URA3</i> insertion</h5>
+
                <figure class="figure">
                  <p>
+
                        <img id="img7" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/9/9b/T--DTU-Denmark--Proins_SDS.png/800px-T--DTU-Denmark--Proins_SDS.png" alt="DESCRIPTION">
                      In order to integrate the <i>URA3</i> gene into the genome of the <i>Y. lipolytica</i> PO1fΔ<i>Ku70</i> strain, we first constructed a pCRISPRyl-derived plasmid which contained a protospacer that targets the <i>PEX10</i> locus. This protospacer was used previously for successful disruption of <i>PEX10</i><sup><a href="#references">8</a></sup>. The pCRISPRyl-derived plasmid (pIW357) was constructed through the Gibson assembly of a 60 bp fragment containing the protospacer of interest into the AvrII linearized pCRISPRyl. Subsequently, pIW357 was purified from selected <i>E. coli</i> DH5ɑ transformants and a double restriction analysis was performed with PstI and AvrII (Figure 13). As the purified pIW357 was no longer digested with AvrII, the protospacer had been correctly inserted. In addition, the protospacer insertion was confirmed through Sanger sequencing (data not shown). 
+
                        <figcaption class="figure-caption"><strong>Figure 6:</strong> SDS page of <i>Y. lipoltyica</i> cell lysate stained with Coomassie blue. The construct the cells were transformed with and the dilution factor of the crude protein extract can be seen above the bands. The weight of the proteins can be seen on the ladders. Notice that no distinct band is visible at the approximate size of proinsulin (9.4kDa).</figcaption>
                  </p>
+
                 
+
                    <figure class="figure">
+
                    <img id="img14" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/f/f8/T--DTU-Denmark--restrictionanalysispstiavrii.png" alt="DESCRIPTION">
+
                    <figcaption class="figure-caption"><strong>Figure 13:</strong> Restriction analysis of pCRISPRyl (lanes 2-3) and pIW357 (lanes 5-8) (left to right). Lane 2: pCRISPRyl digested with PstI. Lane 3: pCRISPRyl digested with PstI and AvrII. Lane 5-8: pIW357 digested with PstI and AvrII (4 unique transformants/plasmids). As pIW357 was digested solely by PstI, it was concluded that the Gibson assembly had been successful and the protospacer had been correctly inserted.</figcaption>
+
 
                     </figure>
 
                     </figure>
  
 
                     <!-- The Modal with same picture-->
 
                     <!-- The Modal with same picture-->
                     <div id="img14Modal" class="modal">
+
                     <div id="img7Modal" class="modal">
                    <span class="close img14">×</span>
+
                        <span class="close img7">×</span>
                    <img class="modal-content" id="img14Img">
+
                        <img class="modal-content" id="img7Img">
                    <div class="caption">DESCRIPTION</div>
+
                        <div class="caption">DESCRIPTION</div>
 
                     </div>
 
                     </div>
                   
+
 
                    <p>
+
                <figure class="figure">
                        Next, we tested pIW357 in the <i>Y. lipolytica</i> PO1fΔ<i>Ku70</i> strain. In order to account for Cas9 activity of pIW357, we also transformed the pCRISPRyl as a positive control. The results of these transformations are depicted in Figure 14. With an intact NHEJ repair pathway and/or a template for HR, the induced DSB should easily be repaired. However, as this is the PO1fΔ<i>Ku70</i> strain and as there is no HR donor template available, cells die, indicating that the pIW357 is functioning properly. The observed residual growth can be attributed to either mutations in pIW357 (for example in Cas9 or in the the sgRNA/tRNA promoter) or possible repair by the Microhomology-Mediated End-Joining (MMEJ) pathway<sup><a href="#references">14</a></sup>.
+
                        <img id="img8" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/thumb/f/f5/T--DTU-Denmark--Proins_WB.jpg/716px-T--DTU-Denmark--Proins_WB.jpg" alt="DESCRIPTION">
                    </p>
+
                        <figcaption class="figure-caption"><strong>Figure 7:</strong> Western Blotting of <i>Y. lipoltyica</i> cell lysate. The lysates was loaded the same way as the SDS page gel above. Notice that only noise is present on the picture.</figcaption>
                   
+
                    <figure class="figure">
+
                    <img id="img15" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/1/10/T--DTU-Denmark--testPS.jpg" alt="DESCRIPTION">
+
                    <figcaption class="figure-caption"><strong>Figure 14:</strong> Transformation of pIW357 and pCRISPRyl into the <i>Y. lipolytica</i> PO1fΔ<i>Ku70</i> strain. pIW357 (A), pCRISPRyl (B), control (C), plated on SC-leu media.</figcaption>
+
 
                     </figure>
 
                     </figure>
  
 
                     <!-- The Modal with same picture-->
 
                     <!-- The Modal with same picture-->
                     <div id="img15Modal" class="modal">
+
                     <div id="img8Modal" class="modal">
                    <span class="close img15">×</span>
+
                        <span class="close img8">×</span>
                    <img class="modal-content" id="img15Img">
+
                        <img class="modal-content" id="img8Img">
                    <div class="caption">DESCRIPTION</div>
+
                        <div class="caption">DESCRIPTION</div>
 
                     </div>
 
                     </div>
                   
+
 
 
                     <p>
 
                     <p>
                         With a functioning pIW357, we then co-transformed pIW357 and pIW501 (linearized) into the <i>Y. lipolytica</i> PO1fΔ<i>Ku70</i> strain (Figure 15). The observation of growth on SC-ura media indicates that the <i>URA3</i> gene had been successfully integrated. Growth was also observed when solely the linearized pIW501 was transformed. In addition, transformants from the co-transformation of pIW357 and pIW501 were screened for <i>URA3</i> integration through gap-check colony PCR (Figure 16). The observed shift in band size between non-pIW501 transformants and pIW501 transformants corresponds to the 1700 bp size of the <i>URA3</i> promoter+CDS+terminator sequence that is present on pIW501.  
+
                         Unfortunately, non of these results gave conclusive evidence for the presence of proinsulin in our samples. The lack of proinsulin on the SDS could be caused by the concentration of proinsulin being lower than the detection limit. The lack of signal in the western blotting results could be caused by <a href="http://www.abcam.com/insulin-antibody-epr3075-ab108326-references.html">our antibody</a> not recognising the proinsulin produced due to incomplete folding, or sub-optimal treatment of the membrane. Of course there is also the possibility that our strain is not producing proinsulin, although due to the positive results using hrGFP we are confident that our expression system works. Other effects such as mRNA folding or rapid protein degradation may also be factors leading to us not being able to detect proinsulin in the samples. Future efforts could include a fusion of the proinsulin a reporter (such as GFP) or a purification tag (such as a His-tag) aiding the detection of proinsulin.
 
                     </p>
 
                     </p>
                   
 
                        <figure class="figure">
 
                        <img id="img16" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/1/1f/T--DTU-Denmark--cotransformation.jpg" alt="DESCRIPTION">
 
                        <figcaption class="figure-caption"><strong>Figure 15:</strong> Co-transformation of pIW357 and linearized pIW501 into the Y. lipolytica PO1fΔKu70 strain. pIW357+linearized pIW501 (A), linearized pIW501 (B), control (C), plated on SC-ura selective media.</figcaption>
 
                        </figure>
 
 
                        <!-- The Modal with same picture-->
 
                        <div id="img16Modal" class="modal">
 
                        <span class="close img16">×</span>
 
                        <img class="modal-content" id="img16Img">
 
                        <div class="caption">DESCRIPTION</div>
 
                        </div>
 
                       
 
                        <figure class="figure">
 
                        <img id="img17" class="enlarge img-responsive figure-img" src="https://static.igem.org/mediawiki/2016/7/7a/T--DTU-Denmark--colonypcrmodified.png" alt="DESCRIPTION">
 
                        <figcaption class="figure-caption"><strong>Figure 16:</strong> Gap-check colony PCR of <i>URA3</i> integration in the <i>PEX10</i> locus of the <i>Y. lipolytica</i> PO1fΔ<i>Ku70</i> strain. The used gap-check primers anneal slightly upstream and downstream of the 1 kb <i>PEX10</i> upstream and downstream flanking regions, respectively. This allows for a direct comparison of the amplicon size between a control transformant and a transformant which should contain the insert in the same PCR reaction. Although only 3 screened co-transformation transformants are depicted in this Figure, an efficiency of 100% was achieved (12/12). Forward primer: TGAGCGAAACGTCATCTACG. Reverse primer: AGCAGTGAAAAGTCGGGCTA.</figcaption>
 
                        </figure>
 
 
                        <!-- The Modal with same picture-->
 
                        <div id="img17Modal" class="modal">
 
                        <span class="close img17">×</span>
 
                        <img class="modal-content" id="img17Img">
 
                        <div class="caption">DESCRIPTION</div>
 
                        </div>
 
                       
 
                        <p>
 
                            The pIW501 is linearized prior to transformation in order to increase HR efficiency and in order to reduce the amount of false positive transformants (a gene cannot be expressed from a linear DNA fragment). However, growth was also observed when solely the pIW501 is transformed, indicating that CRISPR-Cas9 DSB induction is not necessarily required for the integration of an auxotrophic marker gene. We did not have time to compare the efficiencies of co-transformation of pIW357 and pIW501 as compared to solely pIW501 transformation. However, it has been shown previously that co-transformation with a CRISPR-Cas9 plasmid increases the HR efficiency<sup><a href="#references">12</a></sup>. We thus hypothesize that the integration of the <i>URA3</i> gene was facilitated by pIW357. We also did not have time to test the integration of a non-marker gene (which would still allow for an easily selectable phenotype such as <i>GFP</i> or <i>lacZ</i>). This might have been a better option, as the efficiency of non-CRISPR-Cas9 induced HR is lower for a non-marker gene. This would have allowed us to more easily distinguish between CRISPR-Cas9-mediated and non-CRISPR-Cas9-mediated gene integration.
 
                        </p>
 
                       
 
                  <h5 class="h5">2. <i>PEX10</i> deletion</h5>
 
                      <p>
 
                            1
 
                      </p>
 
                                 
 
                             
 
               
 
               
 
 
         </div>
 
         </div>
     
+
       
         <div><a class="anchor" id="section-3"></a>
+
       
 +
       
 +
         <div><a class="anchor" id="section-4"></a>
 
             <h2 class="h2">Conclusion</h2>
 
             <h2 class="h2">Conclusion</h2>
            <p>
+
                <p>
            We successfully developed a shuttle vector that allows the user to harvest the efficiency and accessibility of cloning in <i>E. coli</i>, while still allowing for replication in <i>Y. lipolytica</i>. We extensively tested the plasmid, and showed that it allows for replication, selection in <i>E. coli</i> and replication, selection and even counterselection <i>Y. lipolytica</i>. The plasmid was shown to be compatible with BioBsricks which, to our knowledge, makes it the first tool that allows for the use BioBricks in <i>Y. lipolytica</i>. It is our hope that other actors in iGEM community will use this tool in order harvest the great potentials of <i>Y. lipolytica</i> as a chassis for biorefineries of the future.
+
                    In this section we apply the tools made in the molecular toolbox section, for heterologous protein production in <i>Y. lipolytica</i>. This is done by combining two of our own BioBricks, a constitutive transcription factor alpha (TEF1) promoter native to <i>Y. lipolytica</i> (<a href="http://parts.igem.org/Part:BBa_K2117000">BBa_K2117000</a>) and the hrGFP gene (<a href="http://parts.igem.org/Part:BBa_K2117003">BBa_K2117003</a>) codon optimized by the algorithm developed by our team. By combining these two parts using A3 assembly and the cloning flow suggested in the molecular tools section, we created the device <a href="http://parts.igem.org/Part:BBa_K2117005">BBa_K2117005</a>. By confirming the production of hrGFP, we were able to prove that heterologous protein production is possible when our tool pSB1A8YL. Even though efforts to translate this into proinsulin production failed, the modular nature of pSB1A8YL means that it has potential to become a powerful tool when using <i>Y. lipolytica</i> for research or indsutrial purposes.
            </p><p>
+
                </p>
            As a proof-of-concept, we have shown that we can integrate a gene of interest into <i>Y. lipolytica</i> and also disrupt a native gene of interest. Although in our project we have used a plasmid-based protein expression system this proof-of-concept validates the use of <i>Y. lipolytica</i> for future cell factory engineering purposes. Here, we have focused on the integration of a commonly used auxotrophic marker gene. However, the CRISPR-Cas9 system can be applied for markerless gene integrations<sup><a href="#references">13</a></sup>. Markerless genetic modifications are advantageous as they do not affect cell physiology and allow for iterative genetic modification cycles of the production organism of interest. In addition, this iterative process can be sped up as the modular nature of the CRISPR-Cas9 system makes it ideally suited for simultaneous multiplex genome editing<sup><a href="#references">13,15</a></sup>.
+
        </div>
             </p>  
+
       
 +
        <!-- Reference section -->
 +
        <div id="ref_sec"><a class="anchor" id="references"></a>
 +
            <h2 class="h2">References</h2>
 +
            <ol>
 +
                <li>Blazeck, J., Liu, L., Redden, H., & Alper, H. (2011). Tuning Gene Expression in Yarrowia lipolytica by a Hybrid Promoter Approach. Applied and Environmental Microbiology, 77(22), 7905–7914. doi:10.1128/AEM.05763-11</li>
 +
                <li><a href="https://www.niddk.nih.gov/health-information/diabetes/types/prediabetes-insulin-resistance">NIDDK</li>
 +
                <li>Zaykov, A. N., Mayer, J. P., & DiMarchi, R. D. (2016). Pursuit of a perfect insulin. Nat Rev Drug Discov, 15(6), 425–439. JOUR. Retrieved from http://dx.doi.org/10.1038/nrd.2015.36</li>
 +
                <li>Mayer, J. P., Zhang, F., & DiMarchi, R. D. (2007). Insulin structure and function. Biopolymers, 88(5), 687–713. doi:10.1002/bip.20734</li>
 +
                <li>Baeshen, Nabih A., et al. "Cell factories for insulin production." Microbial cell factories 13.1 (2014): 1.</li>
 +
                <li><a href="http://www.idf.org/sites/default/files/IDF_AnnualReport_2015_WEB.pdf">IDF annual report 2015</li>
 +
             </ol>
 
         </div>
 
         </div>
 
            <!-- Reference section -->
 
    <div id="ref_sec"><a class="anchor" id="references"></a>
 
    <h2 class="h2">References</h2>
 
    <ol>
 
        <li>Shetty, R. P., Endy, D., & Knight, T. F. (2008). Engineering BioBrick vectors from BioBrick parts. Journal of Biological Engineering, 2(1), 5. article. http://doi.org/10.1186/1754-1611-2-5</li>
 
        <li><a href="http://parts.igem.org/Collections">iGEM collections</a></li>
 
        <li>Liu, L., Otoupal, P., Pan, A., & Alper, H. S. (2014). Increasing expression level and copy number of a Yarrowia lipolytica plasmid through regulated centromere function. Fems Yeast Research, 14(7), 1124–1127. doi:10.1111/1567-1364.12201</li>
 
        <li>Yanisch-Perron, C., Vieira, J., & Messing, J. (1984). Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mpl8 and pUC19 vectors. Gene, 33(33), 103–119. doi:10.1016/0378-1119(85)90120-9</li>
 
        <li>Yamane, T., Sakai, H., Nagahama, K., Ogawa, T., & Matsuoka, M. (2008). Dissection of centromeric DNA from yeast Yarrowia lipolytica and identification of protein-binding site required for plasmid transmission. Journal of Bioscience and Bioengineering, 105(6), 571–578. doi:10.1263/jbb.105.571</li>
 
        <li>Liu, L., Otoupal, P., Pan, A., & Alper, H. S. (2014). Increasing expression level and copy number of a Yarrowia lipolytica plasmid through regulated centromere function. Fems Yeast Research, 14(7), 1124–1127. doi:10.1111/1567-1364.12201</li>
 
        <li>Blazeck, J., Liu, L., Redden, H., & Alper, H. (2011). Tuning Gene Expression in Yarrowia lipolytica by a Hybrid Promoter Approach. Applied and Environmental Microbiology, 77(22), 7905–7914. doi:10.1128/AEM.05763-11</li>
 
        <li>Schwartz, C. M., Hussain, M. S., Blenner, M., & Wheeldon, I. (2016). Synthetic RNA Polymerase III Promoters Facilitate High-Efficiency CRISPR-Cas9-Mediated Genome Editing in Yarrowia lipolytica. Acs Synthetic Biology, 5(4), 356–359. doi:10.1021/acssynbio.5b00162</li>
 
        <li>Sakaguchi, T., Nakajima, K., & Matsuda, Y. (2011). Identification of the UMP Synthase Gene by Establishment of Uracil Auxotrophic Mutants and the Phenotypic Complementation System in the Marine Diatom Phaeodactylum tricornutum. Plant Physiol, 156(1), 78–89.</li>
 
        <li><a href="http://parts.igem.org/Help:Plasmid_backbones/Nomenclature">iGEM nomenclature</a></li>
 
        <li>Ronda, C., Maury, J., Jakočiu̅nas, T., Baallal Jacobsen, S. A., Germann, S. M., Harrison, S. J., Borodina, I., Keasling, J. D., Jensen, M. K., & Nielsen, A. T. (2015). CrEdit: CRISPR mediated multi-loci gene integration in Saccharomyces cerevisiae. Microbial Cell Factories, 14(1), 97. http://doi.org/10.1186/s12934-015-0288-3</li>
 
        <li>Nødvig, C. S., Nielsen, J. B., Kogle, M. E., & Mortensen, U. H. (2015). A CRISPR-Cas9 system for genetic engineering of filamentous fungi. PLoS ONE, 10(7), 1–18. http://doi.org/10.1371/journal.pone.0133085</li>
 
        <li>Jessop-Fabre, M. M., Jakočiūnas, T., Stovicek, V., Dai, Z., Jensen, M. K., Keasling, J. D. & Borodina, I. (2016), EasyClone-MarkerFree: A vector toolkit for marker-less integration of genes into Saccharomyces cerevisiae via CRISPR-Cas9. Biotechnology Journal, 11: 1110–1117. doi:10.1002/biot.201600147</li>
 
        <li>Sakuma, T., Nakade, S., Sakane, Y., Suzuki, K.-I. T., & Yamamoto, T. (2015). MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems. Nature Protocols, 11(1), 118–133. http://doi.org/10.1038/nprot.2015.140</li>
 
        <li>Gao, S., Tong, Y., Wen, Z., Zhu, L., Ge, M., Chen, D., Jiang, S., & Yang, S. (2016). Multiplex gene editing of the Yarrowia lipolytica genome using the CRISPR-Cas9 system. Journal of Industrial Microbiology & Biotechnology, 43(8), 1085–1093. http://doi.org/10.1007/s10295-016-1789-8</li>       
 
    </ol>
 
    </div>
 
 
     </div> <!-- /LEFT -->
 
     </div> <!-- /LEFT -->
 
      
 
      
Line 394: Line 229:
 
     <div class="col-md-3 col-sm-2 colRight" id="scrollspy">  
 
     <div class="col-md-3 col-sm-2 colRight" id="scrollspy">  
 
         <ul class="nav" id="sidebar">
 
         <ul class="nav" id="sidebar">
             <li><a href="#section-1">BioBrick plasmid</a></li>
+
             <li><a href="#section-1">Introduction</a></li>          
             <li><a href="#section-2">CRISPR</a></li>
+
             <li><a href="#section-2">hrGFP</a></li>
             <li><a href="#section-3">Conclusion</a></li>
+
             <li><a href="#section-3">Insulin</a></li>
 +
            <li><a href="#section-4">Conclusion</a></li>
 
             <li><a href="#references">References</a></li>
 
             <li><a href="#references">References</a></li>
 
         </ul>
 
         </ul>

Revision as of 17:55, 19 October 2016

New HTML template for the wiki




Bootstrap Example

Products

In the Molecular tools section we developed several molecular tools, potentially allowing us to genetically engineer Y. lipolytica. In this section we apply these tools and attempt to use these to achieve expression in Y. lipoltyca.


Introduction

“Productivity is never an accident. It is always the result of a commitment to excellence, intelligent planning, and focus efforts” 3

Paul J. Meyer It's your life. Live big.<

By developing tools to genetically engineer Yarrowia lipolytica we aim to create a versatile cell factory, which in the future will be able to produce almost any desired product ranging from complex therapeutic proteins to high value chemical compounds. Besides diversity of products cell factory based on Yarrowia lipolytica offers a wide range of substrate tolerance.

We aim to demonstrate this versatility of our Y. lipolytica strain as a cell factory by producing heterologous proteins. Our first attempt is the production of hrGFP, followed by proinsulin. To achieve both of mentioned ideas we apply the pSB1A8YL plasmid, cloning workflow and codon optimization algorithm developed by our team.

hrGFP

Design

In order to test if we were able to clone a of a construct in E. coli pSB1A8YL, which would be expressed, and ultimately prove that we were able to express genes in Y. lipolytica, we chose to develop our own BioBricks. Namely a constitutive transcription factor alpha (TEF1) promoter native to Y. lipolytica (BBa_K2117000) and the hrGFP gene (BBa_K2117003) previously used successfully in Y. lipolytica1. The hrGFP sequence was codon optimized by the algorithm developed by our team. By combining these two parts in a device (BBa_K2117005) the expression should, in theory, be easily detected due to the fluorescence signal produced. The cloning flow can be seen in Figure 1.

DESCRIPTION
Figure 1: Cloning flow of the expression test of pSB1A8YL in Y. lipolytica. The expression of the GFP should yield a flourescent ouput detectable by fluorescence microscopy or fluorometer measurements.

Results

The parts were ordered as gBlocks and assembled in E. coli using A3 assembly. The assembly was confirmed using restriction analysis (See Figure 2), PCR and sequencing (data not shown).

DESCRIPTION
Figure 2: Analytical digestion of the pSB1A8YL containing the BBa_K2117005 device. The fragment lengths can be seen on the ladder, and the restriction enzyme and predicted fragment lengths is stated above the fragments.

Afterwards the construct was transformed into Y. lipolytica PO1f and grown on plates containing selective media. Single colonies were picked and grown in liquid selective media, and subjected to fluorescence microscopy. Figure 3 shows the Y. lipolytica PO1f cells under a confocal laser microscope with 100x magnification. The high fluorescent output from with the BBa_K2117005 construct, proves that the cells are producing hrGFP, and ultimately that our expression system consisting of pSB1A8YL and the TEF1 promoter (BBa_K2117000) can be used for heterologous protein expression in Y. lipolytica.

DESCRIPTION
DESCRIPTION
Figure 3: Fluorescence microscopy conducted by a confocal laser microscope with 100x magnification. A and D are taken using standard brightfield, B and E are taken using the GFP filter and with the excitation laser on and C and F are overlays of the two photos where the black bagground has been removed (C is an overlay of A and B, and F is an overlay of D and E). A, B and C are Y. lipolytica PO1f cells with our GFP expressing device (BBa_K2117005) shuttled by our plasmid pSB1A8YL. D, E and F are Y. lipolytica PO1f cells with the empty pSB1A8YL plasmid, which serves as a control for the GFP signal. Notice that even though the empty vector control shows trace amounts of auto-fluoresence the strain with the GFP expressing device clearly exhibits higher levels of fluorescence, which proves that our expression system works as intended.

Insulin

Our experiments told us that our plasmid was a powerful tool, allowing us to conveniently assembling constructs in E. coli, which would be expressed in Y. lipolytica. Now we wanted to use it to take on the ultimate challange: Could we use this tool to produce proinsulin, and potentially increase the sustainability of insulin production?

Theory

Insulin is a peptrode hormone synthesised in the pacreas, and plays a crucial role in glucose homeostasis and prevents harmful levels of sugar in the blood. Beta-cells in the islets of the pancreas release insulin to the blood stream, which stimulates muscle fat and liver cells to absorb and store glucose from the bloodstream by interacting with insulin-specific receptors2. Diabetes is caused by either immune-mediated destruction of pacreatic islet cells (type 1 diabetes), or pancreatic exhaustion causing insulin resistance (type 2 diabetes). Both types of diabetes is cured by artificially controlling the insulin concentration in the patient by injection3. The treatment of diabetes with insulin was discovered in 1921, and its ability to restore health is so dramatic, that it was initially described in terms such as "the raising of the dead". Considering this it perhaps does not come as a surprise that insulin is often descirbed as one of the most important biomedical events of the last century4, and as the number of adults with diabetes is expected to rise from 415 million today to 642 million in 2040, the relevance of diabetes is higher than ever6. To read more about the insulin market, see our descriptions page.

Insulin biosynthesis

At the first stage insulin is synthesized as a chain of 101 amino acids, called preproinsulin with a molecular weight of 12 Kilo daltons (kDa), which comprises of signal peptide (pre-peptide) and three short chains: A, B and C. The pre-peptide, responsible for directing a nascent polypeptide, is removed from preproinsulin giving the proinsulin consisting of 86 amino acids with a molecular weight of 9.4kDa. Subsequently, the proinsulin is folded and two disulphide bonds are created between chain A and B and one links chain A. In the last step, the C chain is digested from the proinsulin by an exoprotease - carboxypeptidase E. The mature insulin contains chains A and B linked by 3 disulphide bonds and in total comprises of 51 amino acids with a molecular weight of 5.8kDa5.

FIGURE OF INSULIN CHAINS AND CLEAVING

The first insulin was extracted from animals, and E. coli was emplyoed in the production of the A and B chain separately as recombinant DNA technologies progessed. Today insulin is produced in Saccharomyces cerevisiae by a single chain nonnative "miniproinsulin" precursor, which is matured by trypsin and carboxypeptidase B4.

Goal

In order to demonstrate Yarrowia lipolytica as a versatile cell factory we aim to produce proinsulin as an answer to increasing global demand for insulin.

Results

The human proinsulin sequence was obtain from Sures et al. (1980). The sequence was codon optimized for the codon bias of Y. lipolytica using the codon optimization tool developed by our team, and ordered as a gBlock. The proinsulin gene with the RFC10 prefix and suffix was amplified by PCR into our BioBrick BBa_K2117003 and assembled with our TEF1 promoter to form our device BBa_K2117002. This was done in pSB1A8YL using standard A3 assembly. The construct was transformed into E. coli, purified and confirmed using analytical digenstion, PCR and sequencing (data not shown). After confirmation of the construct, it was transformed into Y. lipolytica. The transformants was subjected to colony PCR (see Figure 4). The cloning flow can be seen in Figure 5.

DESCRIPTION
Figure 4: Analytical digestion of the pSB1A8YL containing the BBa_K2117002 device. The fragment lengths can be seen on the ladder, and the primers predicted fragment lengths is stated above the fragments.
DESCRIPTION
Figure 5: The cloning flow of the proinsulin producing strain.

We knew that detecting the proinsulin would be the biggest challange yet, as all previous detections was based on chromoproteins and fluorescence, while this was a protein without any intrinsic detectable signal. We had several considerations for detecting the proinsulin production including rtPCR and ELISA, altough ended up chosing SDS page and Western blotting, as these methods provide excellent sensitivity while some of the experiences running the SDS page experiments could be transfered to the western blotting experiments. The results of these experiments are show in Figure 6 and 7.

DESCRIPTION
Figure 6: SDS page of Y. lipoltyica cell lysate stained with Coomassie blue. The construct the cells were transformed with and the dilution factor of the crude protein extract can be seen above the bands. The weight of the proteins can be seen on the ladders. Notice that no distinct band is visible at the approximate size of proinsulin (9.4kDa).
DESCRIPTION
Figure 7: Western Blotting of Y. lipoltyica cell lysate. The lysates was loaded the same way as the SDS page gel above. Notice that only noise is present on the picture.

Unfortunately, non of these results gave conclusive evidence for the presence of proinsulin in our samples. The lack of proinsulin on the SDS could be caused by the concentration of proinsulin being lower than the detection limit. The lack of signal in the western blotting results could be caused by our antibody not recognising the proinsulin produced due to incomplete folding, or sub-optimal treatment of the membrane. Of course there is also the possibility that our strain is not producing proinsulin, although due to the positive results using hrGFP we are confident that our expression system works. Other effects such as mRNA folding or rapid protein degradation may also be factors leading to us not being able to detect proinsulin in the samples. Future efforts could include a fusion of the proinsulin a reporter (such as GFP) or a purification tag (such as a His-tag) aiding the detection of proinsulin.

Conclusion

In this section we apply the tools made in the molecular toolbox section, for heterologous protein production in Y. lipolytica. This is done by combining two of our own BioBricks, a constitutive transcription factor alpha (TEF1) promoter native to Y. lipolytica (BBa_K2117000) and the hrGFP gene (BBa_K2117003) codon optimized by the algorithm developed by our team. By combining these two parts using A3 assembly and the cloning flow suggested in the molecular tools section, we created the device BBa_K2117005. By confirming the production of hrGFP, we were able to prove that heterologous protein production is possible when our tool pSB1A8YL. Even though efforts to translate this into proinsulin production failed, the modular nature of pSB1A8YL means that it has potential to become a powerful tool when using Y. lipolytica for research or indsutrial purposes.

  • FIND US AT:
Facebook Twitter
  • DTU BIOBUILDERS
  • DENMARK
  • DTU - SØLTOFTS PLADS, BYGN. 221/002
  • 2800 KGS. LYNGBY

  • E-mail:
  • dtu-biobuilders-2016@googlegroups.com
  • MAIN SPONSORS:
Lundbeck fundation DTU blue dot Lundbeck fundation Lundbeck fundation